Clinical Trial Update: Anagrelide Retard in Essential Thrombocythemia [Phase 3]

View source ↗

Summary

Phase 3 trial update for Anagrelide Retard in essential thrombocythemia; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• Anagrelide Retard (anagrelide)

Snippet

Sponsor: AOP Orphan Pharmaceuticals AG | Conditions: Essential Thrombocythemia | Phase 3 | Status: COMPLETED